The Indian Council of Medical Research (ICMR) has said that the Indian vaccine against COVID-19, Covaxin, has drawn global attention. In a tweet, the ICMR said, "India's indigenous vaccine against #COVID19 Covaxin-a product of ICMR-Bharat Biotech collaboration, achieves remarkable feat. Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet's interest in publishing them."The ICMR said, "Encouraging Phase I and Phase II COVAXIN trial results have paved the path for Phase III Clinical Trial in India, which is currently ongoing at 22 sites."
???????????????????????? ???????????????????????????? ???????????????????????????? ????????????????????-19 ???????????????????? ???????????????????????? ????????????????????????????????????. The results of the #COVAXIN Phase-2 human clinical trials can be accessed at https://t.co/jjl1WifW2q pic.twitter.com/VKfvjeZuOE
— ICMR (@ICMRDELHI) December 24, 2020
Related Posts
Jaishankar discusses Global, Regional Issues with EU & V4 leaders
Bhupender Yadav calls for Global action on conservation
Guterres calls for global unity, peace ahead of ‘last UNGA’ as S.G.